Insiders Could Have Profited By Holding Onto Rocket Pharmaceuticals Shares Despite 13% Drop

Simply Wall StFeb 26 08:24 ET

Rocket Pharmaceuticals Executives Cash Out: See Who Sold Big!

TipRanksFeb 25 21:03 ET

Rocket Pharmaceuticals (RCKT) Loses -12.5% in 4 Weeks, Here's Why a Trend Reversal May Be Around the Corner

Zacks Jan 15 08:40 ET

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), CareDx (CDNA) and Intellia Therapeutics (NTLA)

TipRanksJan 14 06:30 ET · Ratings

J.P. Morgan Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $48

Moomoo NewsJan 8 08:30 ET · Ratings

Rocket Pharmaceuticals Price Target Lowered to $48 From $49 at JPMorgan

TipRanksJan 8 07:40 ET

Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $32

Moomoo NewsJan 6 08:34 ET · Ratings

Buy Recommendation for Rocket Pharmaceuticals: Promising Potential of RP-L301 in Severe PKD Cases

TipRanksJan 6 08:25 ET

Top 3 Health Care Stocks That Could Blast Off This Month

BenzingaJan 6 07:19 ET

BofA Securities Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Maintains Target Price $37

Moomoo NewsJan 6 06:31 ET · Ratings

Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

BusinesswireJan 2 16:00 ET

Major firms rating丨Wedbush: Initiated coverage on Rocket Pharmaceuticals with an "Outperform" rating.

Wedbush initiates coverage of Rocket Pharmaceuticals with an "Outperform" rating and a Target Price of $32. Ongoing pipeline development and internal capacity are expected to support the company's long-term growth potential. (Gelonghui)

Gelonghui FinanceDec 31, 2024 02:56 ET

Sector Update: Health Care Stocks Softer Late Afternoon

MT NewswiresDec 30, 2024 15:56 ET

Rocket Pharmaceuticals' Continued Pipeline Development to Support Long-Term Growth Potential, Wedbush Says

MT NewswiresDec 30, 2024 11:04 ET

Wedbush Starts Rocket Pharmaceuticals With Outperform Into 'Inflection Year'

TipRanksDec 30, 2024 08:05 ET

Wedbush Maintains Rocket Pharmaceuticals(RCKT.US) With Buy Rating, Cuts Target Price to $32

Moomoo NewsDec 30, 2024 07:31 ET · Ratings

Promising Pipeline and Strategic Developments Propel Rocket Pharmaceuticals to 'Buy' Rating

TipRanksDec 30, 2024 06:55 ET · Ratings

Express News | Rocket Pharmaceuticals Inc : Wedbush Initiates Coverage With Outperform Rating; Price Target $32

ReutersDec 30, 2024 06:42 ET

Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right Now?

Yahoo FinanceDec 29, 2024 06:43 ET

Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy'

InvestopediaDec 18, 2024 14:16 ET